Brief: Assembly Biosciences Inc By Mid-Year 2024 Abi-5366, Is Expected To Enter A First-In-Human Clinical Study

Assembly Biosciences

04/01/2024 13:43

Jan 4 (Reuters) - Assembly Biosciences Inc  ASMB.O :
    * BY MID-YEAR 2024 ABI-5366, IS EXPECTED TO ENTER A
FIRST-IN-HUMAN
CLINICAL STUDY
    * ABI-4334, IS ANTICIPATED TO ENTER A PHASE 1B STUDY IN
CHRONIC
HEPATITIS B VIRUS PATIENTS. BY END OF 2024
    * INITIAL CLINICAL DATA EXPECTED TO BE AVAILABLE FROM
ABI-5366
FIRST-IN-HUMAN CLINICAL STUDY & ABI-4334 PHASE 1B STUDY BY
MID-YEAR 2024

Source text for Eikon:  ID:nGNX9LXkB9 
Further company coverage:  ASMB.O 

 ((Reuters.Briefs@thomsonreuters.com;))